We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ambulatory Surgery Centers: A Long-Term Growth Opportunity for ISRG?
Read MoreHide Full Article
Key Takeaways
Intuitive Surgical is aligning with the shift of procedures to ASCs and outpatient settings.
ISRG sees ASCs as a long-term growth driver, supported by XiR systems and trained surgeons.
Intuitive Surgical notes ASC growth, high utilization and suitable procedures for robotic efficiency.
Intuitive Surgical (ISRG - Free Report) is increasingly aligning its strategy with the ongoing migration of surgical procedures toward lower-cost care settings, particularly ambulatory surgery centers (ASCs). Management noted a clear trend of procedures shifting from hospitals to hospital outpatient departments and ASCs, driven by payer incentives and the growing feasibility of minimally invasive techniques in these environments.
While ASCs currently represent a relatively small portion of total procedures, they are growing at an accretive rate, signaling a meaningful long-term opportunity for ISRG. The company is actively expanding its footprint in these settings, focusing initially on higher-volume ASCs capable of sustaining robotic programs. About 70% of the ASC opportunity lies within existing IDN networks, where surgeons are already trained on da Vinci systems, reducing adoption friction.
A key enabler of this shift is the introduction of refurbished da Vinci Xi systems (XiR). These systems offer a lower-cost entry point tailored to ASC economics, where reimbursement levels are tighter than in hospitals. Management emphasized that XiR, combined with flexible capital acquisition models and a broader ecosystem of instruments and services, is well suited to meet ASC-specific financial and operational requirements.
From a clinical perspective, ASCs are primarily focused on lower-acuity, high-volume procedures, such as cholecystectomy, hernia repair and benign gynecologic surgeries. These cases benefit from standardized workflows, repeatability and predictable outcomes — areas where robotic-assisted surgery can demonstrate efficiency gains.
Economically, the ASC model demands consistent utilization and cost efficiency. ISRG highlighted that existing ASC utilization levels are already “pretty good,” suggesting that robotic programs can be financially viable when case volumes are sufficient.
Overall, while still in early innings, the ASC channel represents a structurally attractive growth space. As procedure migration accelerates and XiR adoption scales, ASCs could become a meaningful contributor to ISRG’s long-term procedure growth and system placements.
Peer Update
Medtronic (MDT - Free Report) is increasingly aligning its growth strategy with the shift toward ambulatory and outpatient care settings, particularly as it scales its surgical and minimally invasive platforms. Medtronic highlighted the U.S. launch of its Hugo robotic system and broader surgical ecosystem, emphasizing flexibility, portability and workflow efficiency — features critical for lower-cost care environments.
MDT’s ability to offer solutions across open, laparoscopic and robotic surgery positions it to support care migration beyond traditional hospitals. As Medtronic expands indications and integrates digital tools like Touch Surgery, it is building a platform that facilitates procedural standardization and efficiency — key enablers for ambulatory settings and long-term volume growth.
Abbott (ABT - Free Report) is also benefiting from the broader migration toward less invasive, site-of-care-agnostic treatment models, particularly within its medical devices portfolio. The company highlighted strong double-digit growth across segments, such as electrophysiology, structural heart and heart failure, driven by technologies that improve procedural efficiency and patient outcomes.
ABT’s focus on minimally invasive devices, such as PFA catheters, implantable sensors and structural heart solutions, supports treatment in lower-acuity environments where shorter recovery times and reduced hospital stays are critical. As Abbott continues to innovate across its device portfolio, it is well positioned to capture incremental procedure volumes as care increasingly shifts toward outpatient and ambulatory settings.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have risen 10.8% over the past six months against 6.8% decline for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 46.7, above the industry average. But, it is still lower than its five-year median of 70.91. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 12.7% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Shutterstock
Ambulatory Surgery Centers: A Long-Term Growth Opportunity for ISRG?
Key Takeaways
Intuitive Surgical (ISRG - Free Report) is increasingly aligning its strategy with the ongoing migration of surgical procedures toward lower-cost care settings, particularly ambulatory surgery centers (ASCs). Management noted a clear trend of procedures shifting from hospitals to hospital outpatient departments and ASCs, driven by payer incentives and the growing feasibility of minimally invasive techniques in these environments.
While ASCs currently represent a relatively small portion of total procedures, they are growing at an accretive rate, signaling a meaningful long-term opportunity for ISRG. The company is actively expanding its footprint in these settings, focusing initially on higher-volume ASCs capable of sustaining robotic programs. About 70% of the ASC opportunity lies within existing IDN networks, where surgeons are already trained on da Vinci systems, reducing adoption friction.
A key enabler of this shift is the introduction of refurbished da Vinci Xi systems (XiR). These systems offer a lower-cost entry point tailored to ASC economics, where reimbursement levels are tighter than in hospitals. Management emphasized that XiR, combined with flexible capital acquisition models and a broader ecosystem of instruments and services, is well suited to meet ASC-specific financial and operational requirements.
From a clinical perspective, ASCs are primarily focused on lower-acuity, high-volume procedures, such as cholecystectomy, hernia repair and benign gynecologic surgeries. These cases benefit from standardized workflows, repeatability and predictable outcomes — areas where robotic-assisted surgery can demonstrate efficiency gains.
Economically, the ASC model demands consistent utilization and cost efficiency. ISRG highlighted that existing ASC utilization levels are already “pretty good,” suggesting that robotic programs can be financially viable when case volumes are sufficient.
Overall, while still in early innings, the ASC channel represents a structurally attractive growth space. As procedure migration accelerates and XiR adoption scales, ASCs could become a meaningful contributor to ISRG’s long-term procedure growth and system placements.
Peer Update
Medtronic (MDT - Free Report) is increasingly aligning its growth strategy with the shift toward ambulatory and outpatient care settings, particularly as it scales its surgical and minimally invasive platforms. Medtronic highlighted the U.S. launch of its Hugo robotic system and broader surgical ecosystem, emphasizing flexibility, portability and workflow efficiency — features critical for lower-cost care environments.
MDT’s ability to offer solutions across open, laparoscopic and robotic surgery positions it to support care migration beyond traditional hospitals. As Medtronic expands indications and integrates digital tools like Touch Surgery, it is building a platform that facilitates procedural standardization and efficiency — key enablers for ambulatory settings and long-term volume growth.
Abbott (ABT - Free Report) is also benefiting from the broader migration toward less invasive, site-of-care-agnostic treatment models, particularly within its medical devices portfolio. The company highlighted strong double-digit growth across segments, such as electrophysiology, structural heart and heart failure, driven by technologies that improve procedural efficiency and patient outcomes.
ABT’s focus on minimally invasive devices, such as PFA catheters, implantable sensors and structural heart solutions, supports treatment in lower-acuity environments where shorter recovery times and reduced hospital stays are critical. As Abbott continues to innovate across its device portfolio, it is well positioned to capture incremental procedure volumes as care increasingly shifts toward outpatient and ambulatory settings.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have risen 10.8% over the past six months against 6.8% decline for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 46.7, above the industry average. But, it is still lower than its five-year median of 70.91. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 12.7% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.